Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1974

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

A randomized contraceptive trial comparing a daily progestogen with a

combined oral contraceptive steroid.

AUTHORS

Paulsen ML; Varaday A; Brown BW; Kalman SM

SOURCE

Contraception. 1974 May;9(5):497-506.

ABSTRACT

This study was designed as a double-blind trial of .25 mg ethynodiol diacetate versus the combined, established

preparation, Ovulen 21 (1 mg ethynodiol diacetate and .1 mg mestranol). Blanks were added to the sets of Ovulen 21

capsules so that there was no obvious difference in appearance of the medications. 43 young women enrolled in

each group. There were more dropouts in the experimental group so that the average number of months of study was

9.2 for the control group and only 6.7 for the experimental group. The experimental group reported more intercyclic

bleeding and more irregularity of cycles than the Ovulen 21 control group (p<.001 in each case). Cramping was

reported 3 times more frequently by the experimental group, (p<.05). There was 1 unusually prolonged case of

amenorrhea (7 months) in a patient taking ethynodiol diacetate. This patient responded to discontinuation of the

tablet and had a menstrual cycle within 36 days. There were no unintended pregnancies. (PubHealth.info Document

ID: CONT7T 3508-06)

PubHealth.info NOTE: The author(s) of this article titled, "A randomized contraceptive trial comparing a daily

progestogen with a combined oral contraceptive steroid.", is(are) Paulsen ML; Varaday A; Brown BW; Kalman SM.

The source of this article is "Contraception. 1974 May;9(5):497-506.". This article was published in 1974 in English

language(s). (PubHealth.info® Document ID: CONT7T 3508-06. All rights reserved with PubHealth.info) PIN: 33508

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.